BETACELLTHERAPY
Beta Cell Therapy in Diabetes
| Coordinatore | VRIJE UNIVERSITEIT BRUSSEL
Organization address
address: PLEINLAAN 2 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 15˙919˙619 € |
| EC contributo | 11˙700˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2015-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
VRIJE UNIVERSITEIT BRUSSEL
Organization address
address: PLEINLAAN 2 contact info |
BE (BRUSSEL) | coordinator | 3˙614˙000.00 |
| 2 |
Juvenile Diabetes Research Foundation Center for Beta Cell Therapy in Diabetes
Organization address
address: Laarbeeklaan 103 contact info |
BE (Brussel) | participant | 1˙205˙000.00 |
| 3 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 914˙000.00 |
| 4 |
"VIACYTE, INC CORPORATION"
Organization address
address: GENERAL ATOMICS COURT 3550 contact info |
US (SAN DIEGO CA) | participant | 756˙000.00 |
| 5 |
BETA-CELL
Organization address
address: RESEARCHPARK Z.1. 310 contact info |
BE (ZELLIK) | participant | 756˙000.00 |
| 6 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 502˙000.00 |
| 7 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 500˙000.00 |
| 8 |
SARL ENDOCELLS
Organization address
address: Boulevard Saint Germain 216 contact info |
FR (Paris) | participant | 403˙000.00 |
| 9 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 402˙000.00 |
| 10 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | participant | 402˙000.00 |
| 11 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 402˙000.00 |
| 12 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 402˙000.00 |
| 13 |
UNIVERSITE DE LILLE II - DROIT ET SANTE
Organization address
address: RUE PAUL DUEZ 42 contact info |
FR (Lille) | participant | 402˙000.00 |
| 14 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 360˙000.00 |
| 15 |
Fondazione Centro San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 300˙000.00 |
| 16 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 200˙000.00 |
| 17 |
NORGES TEKNISK-NATURVITENSKAPELIGEUNIVERSITET NTNU
Organization address
address: HOGSKOLERINGEN 1 contact info |
NO (TRONDHEIM) | participant | 180˙000.00 |
| 18 |
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Organization address
address: Via Olgettina 60 contact info |
IT (MILANO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage, inaccessibility of the implants, risks of associated immunosuppression. Our consortium of research, clinical and bioindustry teams is focused on overcoming these obstacles and implementing a roadmap for translation to preclinical models and clinical trials. We will pursue three interacting tracks. First, our ability to induce beta cell progenitors and stimulate beta cell proliferation in vivo should lead us to cells and compounds that activate this process in a diabetic pancreas, thus activating endogenous beta cell regeneration. Second, we will produce human beta (progenitor) cells in vitro by derivation from stem cells as well as from reprogrammed autologous cells; their therapeutic potential will be compared to that of primary human beta cells following implantation in rodents using a site that is accessible to modulation and monitoring. Third, we will design an antibody-based therapy for inducing immune tolerance to regenerated beta cells and to a beta cell implant. Efficacy, safety and regulatory criteria will be determined for clinical implementation. Clinical protocols will be prepared by adjusting associated therapy and by adopting an accessible and controlled implant site. Clinical trials will benefit from state-of-the art biologic markers for comparative analysis of the developed forms of beta cell therapy. This program should provide proof of principle for strategies that make beta cell transplantation and beta cell regeneration realistic for large numbers of type 1 diabetic patients, and probably also for some categories of type 2 diabetes.'
Introduzione (Teaser)
A large multidisciplinary consortium joined forces to provide innovative interventions for diabetes. The group employed different sources of stem cells for transplantation or regenerative approaches to restore insulin production.